
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Key factors in choosing appropriate biologic therapy for a patient with
Following are 5 questions on these topics that are based on a comprehensive review and international expert opinion published in the Journal of Allergy and Clinical Immunology: In Practice by a group of clinicians recognized internationally for knowledge of severe asthma and of biologic medications. Test your endotype IQ.






